The novel beta 2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells
Author(s):
Kraus, M.; Bader, J.; Geurink, P.P.; Weyburne, E.S.; Mirabella, A.C.; Silzle, T.; Shabaneh, T.B.; Linden, W.A. van der; Bruin, G. de; Haile, S.R.; Rooden, E. van; Appenzeller, C.; Li, N.; Kisselev, A.F.; Overkleeft, H.; Driessen, C.
Published
2015
Publication type
Article / Letter to editor
Date issued
2015-10-31
Language
English
Is part of
Haematologica (2015), Vol. 100, no. 10, p. 1350-1360
